Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Scinopharm TaiwanTPE:1789 78 EV-to-EBITDA is 23.62 as of Aug. 23, 2026, which is 9% above its 10-year median of 21.73. GuruFocus rates TPE:1789 with a GF Score™ of 78/100 and a GF Value™ of NT$20.19 (Fairly Valued). The stock has 8 warning signs investors should review. Among 739 Drug Manufacturers companies, Scinopharm Taiwan ranks worse than 73.34% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Scinopharm Taiwan's enterprise value is NT$12,754 Mil.
Scinopharm Taiwan's EBITDA for the trailing twelve months (TTM) ended in Jun. 2026 was NT$540 Mil. Therefore, Scinopharm Taiwan's EV-to-EBITDA for today is 23.62.
The historical rank and industry rank for Scinopharm Taiwan's EV-to-EBITDA or its related term are showing as below:
TPE:1789'
s EV-to-EBITDA Range Over the Past 10 Years
Min: 13.64 Med: 21.73 Max: 42.97
Current: 23.62
During the past 13 years, the highest EV-to-EBITDA of Scinopharm Taiwan was 42.97. The lowest was 13.64. And the median was 21.73.
TPE:1789's EV-to-EBITDA is ranked worse than 73.34% of 739
companies
in the Drug Manufacturers industry
Industry Median: 13.21
vs TPE:1789: 23.62
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Scinopharm Taiwan's PE Ratio (TTM) for today is calculated as:
Scinopharm Taiwan's share price for today is NT$19.45.
Scinopharm Taiwan's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was NT$0.050.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
The historical data trend for Scinopharm Taiwan's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Scinopharm Taiwan's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Scinopharm Taiwan EV-to-EBITDA vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Scinopharm Taiwan's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Scinopharm Taiwan's EV-to-EBITDA falls into.
Scinopharm Taiwan's current Enterprise Value is NT$12,754 Mil.
Scinopharm Taiwan's EBITDA for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was NT$540 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Scinopharm Taiwan (TPE:1789) has a EV-to-EBITDA of 23.62 as of Aug. 23, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Scinopharm Taiwan. This is near median its historical median of 21.73. Over the past decade, Scinopharm Taiwan's EV-to-EBITDA has ranged from 13.64 to 42.97. According to the industry distribution chart, Scinopharm Taiwan ranks #542 out of 739 companies in the Drug Manufacturers industry, placing it in the top 73.3%.
Is Scinopharm Taiwan's EV-to-EBITDA too high?
Scinopharm Taiwan's current EV-to-EBITDA of 23.62 is near median its 10-year median of 21.73. Over the past 10 years, this metric has ranged from a low of 13.64 to a high of 42.97. The Drug Manufacturers industry median EV-to-EBITDA is 13.21. Scinopharm Taiwan's value of 23.62 is 78.8% above this industry median. Based on the distribution chart, Scinopharm Taiwan ranks #542 out of 739 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Scinopharm Taiwan has a GF Score™ of 78/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Scinopharm Taiwan's EV-to-EBITDA compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Scinopharm Taiwan ranks #542 out of 739 companies for EV-to-EBITDA. This places Scinopharm Taiwan in the lower half of its industry. The industry median EV-to-EBITDA is 13.21. Scinopharm Taiwan's value of 23.62 is 78.8% above this benchmark. Historically, Scinopharm Taiwan's own EV-to-EBITDA has ranged from 13.64 to 42.97 over the past decade. While the company's 10-year median is 21.73 vs. the industry median of 13.21, Scinopharm Taiwan has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Drug Manufacturers company?
The median EV-to-EBITDA among Drug Manufacturers companies is 13.21, based on 739 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Scinopharm Taiwan's current EV-to-EBITDA of 23.62 is 78.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Scinopharm Taiwan. For the Drug Manufacturers industry, the median EV-to-EBITDA is 13.21 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Scinopharm Taiwan's current EV-to-EBITDA is 23.62, which is near median its own 10-year median of 21.73. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Scinopharm Taiwan stock overvalued right now?
Based on GuruFocus' analysis, Scinopharm Taiwan (TPE:1789) is currently considered Fairly Valued. The stock's GF Value™ is NT$20.19, compared to a current price of NT$19.45 — trading 3.7% below its estimated fair value. The current EV-to-EBITDA is 23.62, which is near median its 10-year median of 21.73 and 78.8% above the Drug Manufacturers industry median of 13.21. Scinopharm Taiwan's overall GF Score™ is 78/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Scinopharm Taiwan (TPE:1789), the current EV-to-EBITDA is 23.62 as of Aug. 23, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Scinopharm Taiwan (TPE:1789) Overvalued in 2026?
Based on GuruFocus' analysis, Scinopharm Taiwan stock appears to be undervalued.
The current stock price of NT$19.45 is trading 3.7% below its estimated GF Value™ of NT$20.19.
GuruFocus considers Scinopharm Taiwan to be Fairly Valued.
Key valuation signals for TPE:1789:
EV-to-EBITDA: 23.62 (near median its 10-year median of 21.73)
GF Value™: NT$20.19 vs. price of NT$19.45 (3.7% below fair value)
Industry Position: 78.8% above the Drug Manufacturers median (#542 of 739)
No single metric tells the full story. See the TPE:1789 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Scinopharm Taiwan Ltd is mainly engaged in the manufacture of western medicines and other chemical materials, biological technology services, intellectual property rights, international trade, and the research, development, production, manufacture, and sales of Active Pharmaceutical Ingredients (API), albumin medicines, oligonucleotide medicines, peptide medicines, injections, and new small molecule drugs. The Company also provides related consulting and technical services and international trade for the above products. In addition, the Company sells chemical material reprocessed from material recycled from the Company's manufacturing process.
78GF Score
Get the complete analysis for TPE:1789
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TPE:1789 has been successfully added to your 
